Latest filing published 14 Apr 2026 for Veracyte, INC.. Read the official filing
Kevin Richard Haas (senior executive) discloses dealings in 2 companies, chiefly Myriad Genetics Inc and Veracyte, Inc. We count 26 filings; the first trade dates from 28 May 2021 and the latest from 10 April 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The record was last updated on 14 April 2026 with a share grant in Veracyte, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 26 declarations